Multiplex analysis of cytokines/chemokines as biomarkers that differentiate healthy contacts from tuberculosis patients in high endemic settings

Cytokine

Volumn 61, Issue 3, 2013, Pages 747-754

  Anbarasu, D ^a   Ponnu Raja, C ^a   Raja, Alamelu ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Biomarker; Contact specific fractions; Interleukin 6; Platelet derived growth factor; Tuberculosis

Indexed keywords

BACTERIAL PROTEIN; CHEMOKINE; CONTACT SPECIFIC FRACTION; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; PLATELET DERIVED GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC VALUE; ENDEMIC DISEASE; FEMALE; HUMAN; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MALE; MULTIPLE CYTOKINE ASSAY; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; BIOLOGICAL MARKERS; CHEMOKINES; ENDEMIC DISEASES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84875375814     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.031     Document Type: Article

References (52)

1. Grange J.M., Zumla A. The global emergency of tuberculosis: what is the cause?. J Roy Soc Promot Health 2002, 122:78-81.
2. WHO: World Health Organization. Global Tuberculosis Control-Surveillance, Planning, Financing. WHO Report; 2009.
3. Zignol M., Hosseini M.S., Wright A., Weezenbeek C.L., Nunn P., Watt C.J., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485.
4. Jereb J., Etkind S.C., Joglar O.T., Moore M., Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003, 7:S384-S390.
5. Lin P.L., Flynn J.L. Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
6. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282:677-686.
7. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
8. Parida S.K., Kaufmann S.H. The quest for biomarkers in tuberculosis. Drug Discov Today 2010, 15:148-157.
9. Walzl G., Ronacher K., Hanekom W., Scriba T.J., Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
10. Deenadayalan A., Heaslip D., Rajendiran A.A., Velayudham B.V., Frederick S., Yang H.L., et al. Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics 2010, 9:538-549.
11. Deenadayalan A., Sundaramurthi J.C., Raja A. Immunological and proteomic analysis of preparative isoelectric focusing separated culture filtrate antigens of Mycobacterium tuberculosis. Exp Mol Pathol 2010, 88:156-162.
12. Selvakumar N., Sekar M.G., Rahman F., Syamsunder A., Duraipandian M., Wares F., et al. Comparison of variants of carbol-fuchsin solution in Ziehl-Neelsen for detection of acid-fast bacilli. Int J Tuberc Lung Dis 2005, 9:226-229.
13. Chadha V.K. Tuberculin test. Indian J Pediatr 2001, 68:53-58.
14. Devadatta S., Dawson J.J., Fox W., Janardhanam B., Radhakrishna S., Ramakrishnan C.V., et al. Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculosis patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1970, 42:337-351.
15. Domon B., Aebersold R. Mass spectrometry and protein analysis. Science 2006, 312:212-217.
16. Ruhwald M., Bodmer T., Maier C., Jepsen M., Haaland M.B., Eugen-Olsen J., et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008, 32:1607-1615.
17. Chegou N.N., Black G.F., Kidd M., van Helden P.D., Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21.
18. Ruhwald M., Bjerregaard-Andersen M., Rabna P., Eugen-Olsen J., Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009, 2:19.
19. Gagneux S., Small P.M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007, 7:328-337.
20. Kaufmann S.H., Parida S.K. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 2008, 4:219-228.
21. Narayanan S., Gagneux S., Hari L., Tsolaki A.G., Rajasekhar S., Narayanan P.R., et al. Genomic interrogation of ancestral Mycobacterium tuberculosis from south India. Infect Genet Evol 2008, 8:474-483.
22. Ahmed N., Ehtesham N.Z., Hasnain S.E. Ancestral Mycobacterium tuberculosis genotypes in India: implications for TB control programmes. Infect Genet Evol 2009, 9:142-146.
23. Albanna A.S., Reed M.B., Kotar K.V., Fallow A., McIntosh F.A., Behr M.A., et al. Reduced transmissibility of east African Indian strains of Mycobacterium tuberculosis. PLoS One 2011, 6:e25075.
24. Springett V.H., Sutherland I. A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 1994, 75:227-233.
25. Fine P.E., Vynnycky E. The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines. Vaccine 1998, 16:1923-1928.
26. Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol 2011, 814-943.
27. Amicosante M., Ciccozzi M., Markova R. Rational use of immunodiagnostic tools for tuberculosis infection: guidelines and cost effectiveness studies. New Microbiol 2010, 33:93-107.
28. Syed Ahamed Kabeer B., Raman B., Thomas A., Perumal V., Raja A. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 2010, 5:e9051.
29. Pai M., O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008, 29:560-568.
30. Leyten E.M., Arend S.M., Prins C., Cobelens F.G., Ottenhoff T.H., van Dissel J.T. Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 2007, 14:880-885.
31. Selvaraj P., Nisha Rajeswari D., Jawahar M.S., Narayanan P.R. Influence of HLA-DRB1 alleles on Th1 and Th2 cytokine response to Mycobacterium tuberculosis antigens in pulmonary tuberculosis. Tuberculosis (Edinb) 2007, 87:544-550.
32. Mattos A.M., Almeida Cde S., Franken K.L., Alves C.C., Abramo C., de Souza M.A., et al. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 2010, 22:775-782.
33. Leal I.S., Smedegard B., Andersen P., Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun 1999, 67:5747-5754.
34. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kopf M., Kaufmann S.H. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997, 65:4843-4849.
35. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
36. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010, 40(July):1830-1835.
37. Kursar M., Koch M., Mittrucker H.W., Nouailles G., Bonhagen K., Kamradt T., et al. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 2007, 178:2661-2665.
38. Kondrack R.M., Harbertson J., Tan J.T., McBreen M.E., Surh C.D., Bradley L.M. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 2003, 198:1797-1806.
39. Jimenez-Martinez M.C., Linares M., Baez R., Montano L.F., Martinez-Cairo S., Gorocica P., et al. Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 2004, 111:100-106.
40. Waugh D.J. Wilson C The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
41. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majoorov K.B., Scheglov I.V., Orlova M.O., et al. Neutrophil response Mycobacterium tuberculosis infection in genetically susceptible and resistance mice. Infect Immun 2005, 73:1744-1753.
42. Wu B., Huang C., Kato-Maeda M., Hopewell P.C., Daley C.L., Krensky A.M., et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2008, 126:202-210.
43. Juffermans N.P., Verbon A., van Deventer S.J., van Deutekom H., Speelman P., van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 1998, 157:1328-1331.
44. Tsao T.C., Hong J., Li L.F., Hsieh M.J., Liao S.K., Chang K.S. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000, 117:103-109.
45. Duffy D., Dawoodji A., Agger E.M., Andersen P., Westermann J., Bell E.B. Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection. PLoS One 2009, 4:e8272.
46. Davila J., Zhang L., Marrs C.F., Durmaz R., Yang Z. Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. J Biomed Biotechnol 2010, 208371.
47. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
48. Davidow A., Kanaujia G.V., Shi L., Kaviar J., Guo X., Sung N., et al. Antibody profiles characteristic of Mycobacterium tuberculosis infection state. Infect Immun 2005, 73:6846-6851.
49. Leyten E.M., Lin M.Y., Franken K.L., Friggen A.H., Prins C., van Meijgaarden K.E., et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006, 8:2052-2060.
50. Sester U., Fousse M., Dirks J., Mack U., Prasse A., Singh M., et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One 2011, 6:e17813.
51. Goletti D., Raja A., Syed Ahamed Kabeer B., Rodrigues C., Sodha A., Carrara S., et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?. PLoS One 2010, 5:e12577.
52. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.